Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Shares Issued (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Shares Issued for 3 consecutive years, with $352000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Shares Issued changed N/A to $352000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$71.3 million, a 43.39% increase, with the full-year FY2023 number at $2.3 million, changed N/A from a year prior.
  • Shares Issued was $352000.0 for Q3 2025 at Inhibrx Biosciences, up from -$71.7 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $198.8 million in Q3 2023 to a low of -$197.7 million in Q4 2023.
  • A 3-year average of $243000.0 and a median of $16.7 million in 2024 define the central range for Shares Issued.
  • Biggest YoY gain for Shares Issued was 63.74% in 2024; the steepest drop was 63.74% in 2024.
  • Inhibrx Biosciences' Shares Issued stood at -$197.7 million in 2023, then soared by 63.74% to -$71.7 million in 2024, then soared by 100.49% to $352000.0 in 2025.
  • Per Business Quant, the three most recent readings for INBX's Shares Issued are $352000.0 (Q3 2025), -$71.7 million (Q4 2024), and $32.9 million (Q2 2024).